Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?

Taylor, Caitlin; Meisel, Jane; Kalinsky, Kevin

Taylor, Caitlin; Meisel, Jane; Kalinsky, Kevin.

Afiliación

Taylor C; Winship Cancer Institute at Emory University, 1365 Clifton Rd NE, Building C, Atlanta, GA 30322-1013, USA.
Meisel J; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, GA, USA.

Ther Adv Med Oncol ; 14: 17588359221084769, 2022.

Article en En | MEDLINE | ID: mdl-35356261

Palabras clave

aromatase inhibitor; breast cancer; hormone receptor-positive breast cancer; molecular testing; neoadjuvant therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google